IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
- Tuesday, January 7, 2020, 7:05
- Finance
- Add a comment
BOSTON, Jan. 7, 2020 /PRNewswire/ — IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the appointment of Michael Cooke, Ph.D., as Chief Scientific Officer. In his…
About the Author
adminasapcorp has written 41552 stories on this site.